Children's Oncology Group's 2013 blueprint for research: neuroblastoma (Q38068818)

28 August 2017

1 reference

title

Children's Oncology Group's 2013 blueprint for research: neuroblastoma (English)

1 reference

28 August 2017

Susan L Cohn

5

0 references

author name string

Julie R Park

1

1 reference

28 August 2017

Rochelle Bagatell

2

1 reference

28 August 2017

Wendy B London

3

1 reference

28 August 2017

John M Maris

4

1 reference

28 August 2017

Katherine K Mattay

6

1 reference

28 August 2017

Michael Hogarty

7

1 reference

28 August 2017

COG Neuroblastoma Committee

8

1 reference

28 August 2017

19 December 2012

1 reference

28 August 2017

Pediatric Blood Cancer

1 reference

28 August 2017

60

1 reference

28 August 2017

6

1 reference

28 August 2017

985-993

1 reference

Recent advances in neuroblastoma

28 August 2017

1 reference

Racial and ethnic disparities in risk and survival in children with neuroblastoma: a Children's Oncology Group study

21 January 2018

1 reference

Replication of neuroblastoma SNP association at the BARD1 locus in African-Americans

21 January 2018

1 reference

Germline PHOX2B mutation in hereditary neuroblastoma

21 January 2018

1 reference

Identification of ALK as a major familial neuroblastoma predisposition gene

21 January 2018

1 reference

Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment.

21 January 2018

1 reference

The International Neuroblastoma Risk Group (INRG) staging system: an INRG Task Force report

21 January 2018

1 reference

The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report

21 January 2018

1 reference

Outcome after surgery alone or with restricted use of chemotherapy for patients with low-risk neuroblastoma: results of Children's Oncology Group study P9641.

21 January 2018

1 reference

Outcome after reduced chemotherapy for intermediate-risk neuroblastoma

21 January 2018

1 reference

Treatment of localised resectable neuroblastoma. Results of the LNESG1 study by the SIOP Europe Neuroblastoma Group.

21 January 2018

1 reference

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

21 January 2018

1 reference

High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial

21 January 2018

1 reference

Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study

21 January 2018

1 reference

Detection of MYCN gene amplification in neuroblastoma by fluorescence in situ hybridization: a pediatric oncology group study.

21 January 2018

1 reference

Chromosome 1p and 11q deletions and outcome in neuroblastoma

21 January 2018

1 reference

Common variations in BARD1 influence susceptibility to high-risk neuroblastoma

21 January 2018

1 reference

Copy number variation at 1q21.1 associated with neuroblastoma

21 January 2018

1 reference

Chromosome 6p22 locus associated with clinically aggressive neuroblastoma

21 January 2018

1 reference

Phenotype restricted genome-wide association study using a gene-centric approach identifies three low-risk neuroblastoma susceptibility Loci.

21 January 2018

1 reference

Integrative genomics identifies LMO1 as a neuroblastoma oncogene

21 January 2018

1 reference

Common variation at 6q16 within HACE1 and LIN28B influences susceptibility to neuroblastoma

21 January 2018

1 reference

Common variation at BARD1 results in the expression of an oncogenic isoform that influences neuroblastoma susceptibility and oncogenicity

21 January 2018

1 reference

Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage

21 January 2018

1 reference

Distinct transcriptional MYCN/c-MYC activities are associated with spontaneous regression or malignant progression in neuroblastomas

21 January 2018

1 reference

Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification

21 January 2018

1 reference

Transcriptional adaptation of neuroblastoma cells to hypoxia

21 January 2018

1 reference

Overall genomic pattern is a predictor of outcome in neuroblastoma

21 January 2018

1 reference

CASZ1b, the short isoform of CASZ1 gene, coexpresses with CASZ1a during neurogenesis and suppresses neuroblastoma cell growth

21 January 2018

1 reference

Mechanisms of CHD5 Inactivation in neuroblastomas

21 January 2018

1 reference

CAMTA1, a 1p36 tumor suppressor candidate, inhibits growth and activates differentiation programs in neuroblastoma cells

21 January 2018

1 reference

CHD5, a tumor suppressor gene deleted from 1p36.31 in neuroblastomas

21 January 2018

1 reference

Association of age at diagnosis and genetic mutations in patients with neuroblastoma.

21 January 2018

1 reference

Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes

21 January 2018

1 reference

Targeting ornithine decarboxylase impairs development of MYCN-amplified neuroblastoma

21 January 2018

1 reference

ODC1 is a critical determinant of MYCN oncogenesis and a therapeutic target in neuroblastoma

21 January 2018

1 reference

Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma

21 January 2018

1 reference

Stabilization of N-Myc is a critical function of Aurora A in human neuroblastoma

21 January 2018

1 reference

Targeting MYC dependence in cancer by inhibiting BET bromodomains

21 January 2018

1 reference

Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma.

21 January 2018

1 reference

Epigenetic changes in pediatric solid tumors: promising new targets

21 January 2018

1 reference

Epigenetic protein families: a new frontier for drug discovery

21 January 2018

1 reference

Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma

21 January 2018

1 reference

Promising therapeutic targets in neuroblastoma

21 January 2018

1 reference

A prospective study of expectant observation as primary therapy for neuroblastoma in young infants: a Children's Oncology Group study.

21 January 2018

1 reference

Screening for neuroblastoma: a resurrected idea?

21 January 2018

1 reference

Profile of neuroblastoma detected by mass screening, resected after observation without treatment: results of the Wait and See pilot study

21 January 2018

1 reference

Neuroblastoma Screening at One Year of Age

21 January 2018

1 reference

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).

21 January 2018

1 reference

Differentiating agents in pediatric malignancies: retinoids in neuroblastoma.

21 January 2018

1 reference

Retinoid therapy of childhood cancer.

21 January 2018

1 reference

Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial

21 January 2018

1 reference

Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study

21 January 2018

1 reference

The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97.

21 January 2018

1 reference

Multivariate analysis of risk factors in stage 4 neuroblastoma patients over the age of one year treated with megatherapy and stem-cell transplantation: a report from the European Bone Marrow Transplantation Solid Tumor Registry.

21 January 2018

1 reference

Metastatic neuroblastoma in children older than one year: prognostic significance of the initial metaiodobenzylguanidine scan and proposal for a scoring system.

21 January 2018

1 reference

Correlation of early metastatic response by 123I-metaiodobenzylguanidine scintigraphy with overall response and event-free survival in stage IV neuroblastoma.

21 January 2018

1 reference

Evaluation of semi-quantitative scoring system for metaiodobenzylguanidine (mIBG) scans in patients with relapsed neuroblastoma.

21 January 2018

1 reference

Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force

21 January 2018

1 reference

Accurate outcome prediction in neuroblastoma across independent data sets using a multigene signature

21 January 2018

1 reference

Prognostic impact of gene expression-based classification for neuroblastoma.

21 January 2018

1 reference

Global genomic and RNA profiles for novel risk stratification of neuroblastoma

21 January 2018

1 reference

Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification

21 January 2018

1 reference

Clinical significance of tumor-associated inflammatory cells in metastatic neuroblastoma

21 January 2018

1 reference

Fractionated low-dose radiotherapy after myeloablative stem cell transplantation for local control in patients with high-risk neuroblastoma

21 January 2018

1 reference

Feasibility of dosimetry-based high-dose 131I-meta-iodobenzylguanidine with topotecan as a radiosensitizer in children with metastatic neuroblastoma

21 January 2018

1 reference

[131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter

21 January 2018

1 reference

Phase I dose escalation of iodine-131-metaiodobenzylguanidine with myeloablative chemotherapy and autologous stem-cell transplantation in refractory neuroblastoma: a new approaches to Neuroblastoma Therapy Consortium Study.

21 January 2018

1 reference

Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma

21 January 2018

1 reference

Busulfan pharmacokinetics following intravenous and oral dosing regimens in children receiving high-dose myeloablative chemotherapy for high-risk neuroblastoma as part of the HR-NBL-1/SIOPEN trial.

21 January 2018

1 reference

Busulfan in hematopoietic stem cell transplant setting

21 January 2018

1 reference

Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity

21 January 2018

1 reference

Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy.

21 January 2018

1 reference

A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group

21 January 2018

1 reference

Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study

21 January 2018

1 reference

Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro

21 January 2018

1 reference

Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study

21 January 2018

1 reference

Irinotecan plus temozolomide for relapsed or refractory neuroblastoma.

21 January 2018

1 reference

Pediatric phase I trial and pharmacokinetic study of MLN8237, an investigational oral selective small-molecule inhibitor of Aurora kinase A: a Children's Oncology Group Phase I Consortium study

21 January 2018

1 reference

Stage 2 combination testing of rapamycin with cytotoxic agents by the Pediatric Preclinical Testing Program

21 January 2018

1 reference

Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growth in vitro and in vivo

21 January 2018

1 reference

Phase I study of temsirolimus in pediatric patients with recurrent/refractory solid tumors

21 January 2018

1 reference

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

21 January 2018

1 reference

Chronic health conditions in adult survivors of childhood cancer

21 January 2018

1 reference

Design issues of randomized phase II trials and a proposal for phase II screening trials

21 January 2018

1 reference

Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group

21 January 2018

1 reference

Excellent Outcome With Reduced Treatment in Infants With Nonmetastatic and Unresectable Neuroblastoma WithoutMYCNAmplification: Results of the Prospective INES 99.1

21 January 2018

1 reference

Early selection in a randomized phase II clinical trial

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/PBC.24433

1 reference

28 August 2017

1 reference